Theratechnologies Initiates Canadian Distribution of EGRIFTA™

Theratechnologies Inc. (TSX:TH) announced that EGRIFTA™ will be available to patients in Canada as the first shipment of the product was sent to McKesson Canada’s specialty wholesale group today.

As quoted in the press release:

In addition, the availability of EGRIFTA™ in Canada will also enable AOP Orphan Pharmaceutical in Vienna, Austria, Theratechnologies’ European partner, to initiate named-patients sales programs in Europe. Indeed, it will be the Canadian presentation of EGRIFTA™ that will be distributed through Theratechnologies’ European partner.

Luc Tanguay, president and CEO of Theratechnologies, commented:

We are especially proud to reach this new milestone. Discovering a new medical treatment and bringing it to market is something that very few Canadian biotech or pharma companies have been able to accomplish. Having our product available in our home country gives us a great sense of pride. First quarter results for 2015 demonstrated the tangible and positive impact of regaining rights to EGRIFTA™ in the United States. The addition of new territories can only be beneficial to our overall objectives of becoming profitable and sustaining growth for the Company.

Click here to read the full Theratechnologies Inc. (TSX:TH) press release.